HealthDay News recently reported on an article in the New England Journal of Medicine, A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease,  that discussed the efficacy and safety of ZED1227, an experimental celiac disease drug that was found to be able to prevent intestinal damage in a preliminary trial. The Celiac Disease Foundation knows how challenging it can be to maintain a gluten-free diet, so having a potential drug like this one to protect against cross-contact and accidental gluten exposure could be essential to improving the health and quality of life of those with celiac disease. While the drug is still in its early trial stages, Dr. Joseph Murray, CDF Medical Advisory Board member, calls the findings encouraging, though cautions that larger studies are needed to determine if the drug will lessen patient symptoms and improve their quality of life. Read more about the findings and their potential impact on the celiac disease community here.


Would you like to participate in celiac disease research? Add your data to our iCureCeliac® patient registry today. iCureCeliac® is a free online portal for patients, or their caregivers, to provide critical insights into life with celiac disease. Your participation will help create better diagnostic tools and treatments for cross-contact and gluten consumption, governmental policy changes, and access to new and innovative clinical trials nationwide, which may, one day, cure celiac disease.